Matrix production and remodeling capacity of cardiomyocyte progenitor cells during in vitro differentiation

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 4, 2012, Pages 497-508

  Bax, Noortje A M ^a   van Marion, Mieke H ^a   Shah, Bhakti ^a   Goumans, Marie José ^b   Bouten, Carlijn V C ^a   Van Der Schaft, Daisy W J ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiac remodeling; Cell differentiation; Extracellular matrix; Human cardiac progenitor cell; Regenerative medicine

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; ELASTIN; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ARTICLE; CARDIOMYOCYTE PROGENITOR CELL; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; STEM CELL;

CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN; ELASTIN; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; STEM CELLS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84865553272     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.07.003     Document Type: Article

References (49)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation Feb. 1 2011, 123:e18-e209.
2. Lindsey M.L., Mann D.L., Entman M.L., Spinale F.G. Extracellular matrix remodeling following myocardial injury. Ann Med 2003, 35:316-326.
3. Passier R., van Laake L.W., Mummery C.L. Stem-cell-based therapy and lessons from the heart. Nature May 15 2008, 453:322-329.
4. Smits A.M., Ramkisoensing A.A., Atsma D.E., Goumans M.-J. Young at heart. An update on cardiac regeneration. Minerva Med Aug. 2010, 101:255-270.
5. Mummery C., Goumans M.-J. Shedding new light on the mechanism underlying stem cell therapy for the heart. Mol Ther Jul. 2011, 19:1186-1188.
6. Hansson E.M., Lindsay M.E., Chien K.R. Regeneration next: toward heart stem cell therapeutics. Cell Stem Cell Oct. 2 2009, 5:364-377.
7. Smits A.M., van Vliet P., Metz C.H., Korfage T., Sluijter J.P., Doevendans P.A., et al. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc 2009, 4:232-243.
8. van Vliet P., Roccio M., Smits A.M., Van Oorschot A.A.M., Metz C.H.G., van Veen T.A.B., et al. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Neth Heart J May 2008, 16:163-169.
9. van Vliet P., Sluijter J.P.G., Doevendans P.A., Goumans M.-J. Isolation and expansion of resident cardiac progenitor cells. Expert Rev Cardiovasc Ther Jan. 2007, 5:33-43.
10. Messina E., De Angelis L., Frati G., Morrone S., Chimenti S., Fiordaliso F., et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res Oct. 29 2004, 95:911-921.
11. Smits A.M., van Laake L.W., Ouden den K., Schreurs C., Szuhai K., van Echteld C.J., et al. Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovasc Res Aug. 1 2009, 83:527-535.
12. Moore L., Fan D., Basu R., Kandalam V., Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPs) in heart failure. Heart Fail Rev Jun. 30 2011, 10.1007/s10741-011-9266-y.
13. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res Jan. 1 2005, 65:40-51.
14. Mizuno T., Yau T.M., Weisel R.D., Kiani C.G., Li R.-K. Elastin stabilizes an infarct and preserves ventricular function. Circulation Aug. 30 2005, 112:I81-I88.
15. Ross R.S., Borg T.K. Integrins and the myocardium. Circ Res Jun. 8 2001, 88:1112-1119.
16. Blankesteijn W.M., Creemers E., Lutgens E., Cleutjens J.P., Daemen M.J., Smits J.F. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand Sep. 2001, 173:75-82.
17. Webb C.S., Bonnema D.D., Ahmed S.H., Leonardi A.H., McClure C.D., Clark L.L., et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation Sep. 5 2006, 114:1020-1027.
18. Vanhoutte D., Schellings M., Pinto Y., Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res Feb. 15 2006, 69:604-613.
19. Li Y.Y., Feldman A.M., Sun Y., McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation Oct. 27 1998, 98:1728-1734.
20. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res Mar. 22 2002, 90:520-530.
21. Goumans M.-J., de Boer T.P., Smits A.M., van Laake L.W., van Vliet P., Metz C.H.G., et al. TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res Nov. 2007, 1:138-149.
22. de Kleijn D.P., Sluijter J.P., Smit J., Velema E., Richard W., Schoneveld A.H., et al. Furin and membrane type-1 metalloproteinase mRNA levels and activation of metalloproteinase-2 are associated with arterial remodeling. FEBS Lett Jul. 13 2001, 501:37-41.
23. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method. Methods Dec. 25 2001, 4:402-408.
24. Bujak M., Frangogiannis N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res May 1 2007, 74:184-195.
25. Minato A., Ise H., Goto M., Akaike T. Cardiac differentiation of embryonic stem cells by substrate immobilization of insulin-like growth factor binding protein 4 with elastin-like polypeptides. Biomaterials Jan 2012, 33:515-523.
26. Kurazumi H., Kubo M., Ohshima M., Yamamoto Y., Takemoto Y., Suzuki R., et al. The effects of mechanical stress on the growth, differentiation, and paracrine factor production of cardiac stem cells. PLoS One 2011, 6:e28890.
27. Sato H., Takahashi M., Ise H., Yamada A., Hirose S.-I., Tagawa Y.-I., et al. Collagen synthesis is required for ascorbic acid-enhanced differentiation of mouse embryonic stem cells into cardiomyocytes. Biochem Biophys Res Commun Mar. 31 2006, 342:107-112.
28. Shamhart P.E., Meszaros J.G. Non-fibrillar collagens: key mediators of post-infarction cardiac remodeling?. J Mol Cell Cardiol Mar. 2010, 48:530-537.
29. Narazaki G., Uosaki H., Teranishi M., Okita K., Kim B., Matsuoka S., et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation Jul. 29 2008, 118:498-506.
30. Ulrich M.M., Janssen A.M., Daemen M.J., Rappaport L., Samuel J.L., Contard F., et al. Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol Sep. 1997, 29:2533-2543.
31. Battista S., Guarnieri D., Borselli C., Zeppetelli S., Borzacchiello A., Mayol L., et al. The effect of matrix composition of 3D constructs on embryonic stem cell differentiation. Biomaterials Nov. 2005, 26:6194-6207.
32. Wu X., Sun Z., Foskett A., Trzeciakowski J.P., Meininger G.A., Muthuchamy M. Cardiomyocyte contractile status is associated with differences in fibronectin and integrin interactions. Am J Physiol Heart Circ Physiol Jun. 2010, 298:H2071-H2081.
33. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev Oct. 2007, 87:1285-1342.
34. Tchetverikov I., Verzijl N., Huizinga T.W., TeKoppele J.M., Hanemaaijer R., DeGroot J. Active MMPs captured by alpha 2 macroglobulin as a marker of disease activity in rheumatoid arthritis. Clin Exp Rheumatol Oct. 2003, 21:711-718.
35. Winter E.M., van Oorschot A.A.M., Hogers B., van der Graaf L.M., Doevendans P.A., Poelmann R.E., et al. A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circ Heart Fail Nov. 2009, 2:643-653.
36. van Oorschot A.A.M., Smits A.M., Pardali E., Doevendans P.A., Goumans M.-J. Low oxygen tension positively influences cardiomyocyte progenitor cell function. J Cell Mol Med Feb. 10 2011, 10.1111/j.1582-4934.2011.01270.x.
37. Mannello F., Tonti G.A.M., Bagnara G.P., Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells Mar. 2006, 24:475-481.
38. Kawai T., Takahashi T., Esaki M., Ushikoshi H., Nagano S., Fujiwara H., et al. Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ J Jul. 2004, 68:691-702.
39. Young D.A., Gavrilov S., Pennington C.J., Nuttall R.K., Edwards D.R., Kitsis R.N., et al. Expression of metalloproteinases and inhibitors in the differentiation of P19CL6 cells into cardiac myocytes. Biochem Biophys Res Commun Sep. 24 2004, 322:759-765.
40. Coker M.L., Doscher M.A., Thomas C.V., Galis Z.S., Spinale F.G. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Aug. 1999, 277:H777-H787.
41. Kassiri Z., Khokha R. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost Feb. 2005, 93:212-219.
42. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation Sep. 16 2003, 108:1395-1403.
43. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem Nov. 29 1996, 271:30375-30380.
44. Li Y.Y., McTiernan C.F., Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res May 2000, 46:214-224.
45. Haan den M.C., Grauss R.W., Smits A.M., Winter E.M., van Tuyn J., Pijnappels D.A., et al. Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischemic mouse hearts. J Cell Mol Med Oct. 18 2011, 10.1111/j.1582-4934.2011.01468.x.
46. Radisic M., Euloth M., Yang L., Langer R., Freed L.E., Vunjak-Novakovic G. High-density seeding of myocyte cells for cardiac tissue engineering. Biotechnol Bioeng May 20 2003, 82:403-414.
47. Zimmermann W.H., Melnychenko I., Eschenhagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials Apr. 2004, 25:1639-1647.
48. Jourdan-Lesaux C., Zhang J., Lindsey M.L. Extracellular matrix roles during cardiac repair. Life Sci Sep. 25 2010, 87:391-400.
49. Vanhoutte D., Heymans S. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. J Mol Cell Cardiol Mar. 2010, 48:445-453.